JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2021, Vol. 41 ›› Issue (8): 1033-1040.doi: 10.3969/j.issn.1674-8115.2021.08.006

• Basic research • Previous Articles     Next Articles

Expression and prognosis analysis of MRPL12 in lung adenocarcinoma

Lei XIONG1(), Qian YI2, Ming-fang XU3, Jian CHEN1()   

  1. 1.Outpatient Service Operating Room, Chongqing Yubei District People's Hospital, Chongqing 401120, China
    2.Department of Paediatric Internal Medicine, Chongqing Youyou Baby Women's and Children's Hospital, Chongqing 401120, China
    3.Department of Oncology, Featured Medical Center of The Chinese People's Liberation Army, Chongqing 400042, China
  • Online:2021-08-28 Published:2021-08-13
  • Contact: Jian CHEN;
  • Supported by:
    Natural Science Foundation of Chongqing(cstc2020jcyj-msxmX0233)

Abstract: Objective

·To analyze the difference of expression of mitochondrial ribosomal protein L12 (MRPL12) in lung adenocarcinoma (LUAD) and normal tissues and its influence on the prognosis of patients, and predict its biological function.


·The expressions of MRPL12 in different cancer tissues were analyzed by The Cancer Genome Atlas (TCGA) using the tumor-infiltrating immune cell analysis database TIMER and GEPIA (gene expression profiling and interactive analyses) server. The expressions of MRPL12 in different types of cancer were analyzed by Sangerbox bioinformatics platform. Cox regression and Kaplan-Meier survival analysis were used and the hazard ratios (HR), the 95% confidence intervals (CI) and the Log-rank P values were evaluated. The LinkedOmics database was used to identify the genes associated with MRPL12 expression. The DAVID database was used for the enrichment analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. The transcription levels of MRPL12 in cells were verified by quantitative PCR (qPCR).


·MRPL12 was highly expressed in many cancer types. But only the LUAD patients with high MRPL12 expression had lower overall survival (OS) and disease-specific survival (DSS). The expression of MRPL12 protein increased with tumor stage and individual tumor grade. The genes negatively related to MRPL12 were enriched into several cancer-related pathways in LUAD gene expression data set, including pathways in cancer (P=0.000), proteoglycans in cancer (P=0.000) and non-small cell lung cancer (P=0.000). The mRNA expression levels of MRPL12 in the LUAD cells (H1395, H1975 and HCC827) were higher than that in the normal cell (Beas-2B), and the difference was statistically significant (P<0.05).


·The LUAD patients with high expression of MRPL12 may have poor prognosis, and thus MRPL12 can be a potential biomarker and potential therapeutic target for LUAD.

Key words: lung adenocarcinoma (LUAD), mitochondrial ribosomal protein L12 (MRPL12), survival analysis, prognosis, biomarker, therapeutic target

CLC Number: